• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

AI-based Drug Design and Development in the Cloud

Cloud Pharmaceuticals is a clinical stage biopharmaceutical company that is a leader in the burgeoning field of Artificial Intelligence based drug development.  The company partners, designs, develops, and licenses novel drug compounds for a wide range of medical indications to the pharmaceutical, biotechnology and medical research markets.  Novel drugs are developed through vertical holdings, typically LLCs for specific therapeutic areas.  Cloud is developing a new class of poly-pharmacy therapeutics based on complex systems dynamics.  In addition, Cloud is launching a pre-competitive database of hits for the entire druggable genome by the end of 2020.  Cloud's objective is to own and liberally share the largest class of molecular IP ever developed.
The company launched in 2011 with a technology license from Duke University, and has since expanded through early stage funding arrangements from Microsoft, the National Science Foundation, and the University of Florida via its Gatorade royalty fund, and has established collaborations with Glaxosmithkline (“GSK”) and Fujitsu.  The company is currently raising its Series B round to further development of its leading programs and to accelerate discovery from the start to IND to 120 days.  Cloud's new accelerated approach is based on novel developments, including quantum computing technology developed with Fijitsu, an inhibitor/agonist database for the druggable genome, a complex systems dynamics approach to polypharmacy design, and reinforcement learning AI.
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com